Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Academic Article uri icon

Overview

abstract

  • We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72-0.97). Lymphoma-related mortality (HR, 0.46; 0.23-0.93) and overall survival (HR, 0.63; 0.41-0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770-775, 2016. © 2016 Wiley Periodicals, Inc.

publication date

  • May 24, 2016

Research

keywords

  • Lymphoma, Follicular

Identity

PubMed Central ID

  • PMC5564298

Scopus Document Identifier

  • 84978224589

Digital Object Identifier (DOI)

  • 10.1002/ajh.24401

PubMed ID

  • 27124800

Additional Document Info

volume

  • 91

issue

  • 8